PH30270A - Method of treating immunoinflammatory disease - Google Patents

Method of treating immunoinflammatory disease

Info

Publication number: PH30270A
Authority: PH; Philippines
Prior art keywords: medicament; treating immunoinflammatory; pref; immunoinflammatory disease; treating
Prior art date: 1991-09-17

Application number

PH44946A

Other languages

English (en)

Inventor

Craig Eugene Caufield

Surendra N Sehgal

John H Musser

Original Assignee

American Home Prod

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-09-17

Filing date

1992-09-16

Publication date

1997-02-20

1992-09-16 Application filed by American Home Prod filed Critical American Home Prod

1997-02-20 Publication of PH30270A publication Critical patent/PH30270A/en

Links

201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
230000000495 immunoinflammatory effect Effects 0.000 title abstract 2
239000003814 drug Substances 0.000 abstract 3
229930105110 Cyclosporin A Natural products 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
229960001265 ciclosporin Drugs 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
229960002930 sirolimus Drugs 0.000 abstract 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
230000000699 topical effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

PH44946A 1991-09-17 1992-09-16 Method of treating immunoinflammatory disease PH30270A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US76112091A	1991-09-17	1991-09-17

Publications (1)

Publication Number	Publication Date
PH30270A true PH30270A (en)	1997-02-20

Family

ID=25061205

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH44946A PH30270A (en)	1991-09-17	1992-09-16	Method of treating immunoinflammatory disease

Country Status (23)

Country	Link
US (1)	US5286730A (cs)
EP (1)	EP0533433B1 (cs)
JP (1)	JP2810599B2 (cs)
KR (1)	KR100299394B1 (cs)
AT (1)	ATE151289T1 (cs)
AU (1)	AU659868B2 (cs)
CA (1)	CA2078379C (cs)
CZ (1)	CZ281900B6 (cs)
DE (1)	DE69218864T2 (cs)
DK (1)	DK0533433T3 (cs)
ES (1)	ES2100297T3 (cs)
GR (1)	GR3023680T3 (cs)
HK (1)	HK108697A (cs)
HU (1)	HU211112B (cs)
IL (3)	IL117640A (cs)
MX (1)	MX9205202A (cs)
NZ (2)	NZ328124A (cs)
PH (1)	PH30270A (cs)
SG (1)	SG43126A1 (cs)
SK (1)	SK279521B6 (cs)
TW (1)	TW212759B (cs)
UA (1)	UA27742C2 (cs)
ZA (1)	ZA927010B (cs)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5286731A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
JP2741285B2 (ja) *	1992-05-22	1998-04-15	千寿製薬株式会社	緑内障治療剤
US5480988A (en) *	1992-10-13	1996-01-02	American Home Products Corporation	Carbamates of rapamycin
US5489680A (en) *	1992-10-13	1996-02-06	American Home Products Corporation	Carbamates of rapamycin
US5434260A (en) *	1992-10-13	1995-07-18	American Home Products Corporation	Carbamates of rapamycin
US5480989A (en) *	1992-10-13	1996-01-02	American Home Products Corporation	Carbamates of rapamycin
CH686761A5 (de) *	1993-05-27	1996-06-28	Sandoz Ag	Galenische Formulierungen.
AT408520B (de) *	1993-05-27	2001-12-27	Novartis Erfind Verwalt Gmbh	Galenische formulierungen
DE4329503A1 (de) *	1993-09-01	1995-03-02	Galenik Labor Freiburg Gmbh	Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
US6204243B1 (en)	1993-09-01	2001-03-20	Novatis Ag	Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US5527907A (en) *	1993-11-19	1996-06-18	Abbott Laboratories	Macrolide immunomodulators
WO1995014023A1 (en) *	1993-11-19	1995-05-26	Abbott Laboratories	Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5389639A (en) *	1993-12-29	1995-02-14	American Home Products Company	Amino alkanoic esters of rapamycin
US5525610A (en) *	1994-03-31	1996-06-11	American Home Products Corporation	42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5463048A (en) *	1994-06-14	1995-10-31	American Home Products Corporation	Rapamycin amidino carbamates
US5849730A (en) *	1994-08-31	1998-12-15	Pfizer Inc.	Process for preparing demethylrapamycins
US5561138A (en) *	1994-12-13	1996-10-01	American Home Products Corporation	Method of treating anemia
US5496832A (en) *	1995-03-09	1996-03-05	American Home Products Corporation	Method of treating cardiac inflammatory disease
FR2736550B1 (fr)	1995-07-14	1998-07-24	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
WO1997031020A1 (en) *	1996-02-22	1997-08-28	The General Hospital Corporation	METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR RESPONSE TO TGF-β LIGANDS
ATE340586T1 (de) *	1996-07-30	2006-10-15	Novartis Pharma Gmbh	Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
CA2270373A1 (en) *	1996-10-31	1998-05-07	American Home Products Corporation	Synergistic composition comprising rapamycin and calcitriol
DE19844397A1 (de) *	1998-09-28	2000-03-30	Hilti Ag	Abrasive Schneidkörper enthaltend Diamantpartikel und Verfahren zur Herstellung der Schneidkörper
US6670355B2 (en) *	2000-06-16	2003-12-30	Wyeth	Method of treating cardiovascular disease
ATE411321T1 (de)	2000-09-19	2008-10-15	Wyeth Corp	Wasserlösliche rapamycin-ester
US6399625B1 (en)	2000-09-27	2002-06-04	Wyeth	1-oxorapamycins
US6399626B1 (en)	2000-10-02	2002-06-04	Wyeth	Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en)	2000-10-02	2002-08-27	Wyeth	Ethers of 7-desmethlrapamycin
US20040018228A1 (en) *	2000-11-06	2004-01-29	Afmedica, Inc.	Compositions and methods for reducing scar tissue formation
TWI286074B (en)	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
KR20020050135A (ko) *	2000-12-20	2002-06-26	조명재	피부 주름 예방 및 완화를 목적으로 하는 피부 외용 조성물
TWI296196B (en) *	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
TWI233359B (en) *	2001-04-06	2005-06-01	Wyeth Corp	Pharmaceutical composition for treating neoplasm
ZA200603888B (en) *	2001-06-01	2007-05-30	Wyeth Corp	Antineoplastic combinations
UA77200C2 (en)	2001-08-07	2006-11-15	Wyeth Corp	Antineoplastic combination of cci-779 and bkb-569
CA2455311A1 (en)	2001-08-22	2003-03-06	Wyeth	Rapamycin dialdehydes
WO2003018573A1 (en)	2001-08-22	2003-03-06	Wyeth	Rapamycin 29-enols
US6641611B2 (en) *	2001-11-26	2003-11-04	Swaminathan Jayaraman	Therapeutic coating for an intravascular implant
ES2485841T3 (es)	2002-02-01	2014-08-14	Ariad Pharmaceuticals, Inc	Compuestos que contienen fósforo y usos de los mismos
RU2344821C2 (ru)	2002-07-30	2009-01-27	Уайт	Парентеральные композиции, содержащие гидроксиэфиры рапамицина
EP1389480A1 (en) *	2002-08-14	2004-02-18	Mondobiotech Interferon SA	Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation
CN100415233C (zh) *	2002-09-17	2008-09-03	惠氏公司	口服制剂
AR042938A1 (es) *	2003-02-06	2005-07-06	Wyeth Corp	Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) *	2003-03-05	2008-07-25	Уайт	Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
EP1615640B1 (en) *	2003-04-22	2007-01-24	Wyeth	Antineoplastic combinations
US20050059583A1 (en)	2003-09-15	2005-03-17	Allergan, Inc.	Methods of providing therapeutic effects using cyclosporin components
ZA200604250B (en) *	2003-11-13	2007-11-28	Combinatorx Inc	Methods and reagents for the treatment of inflammatory disorders
EP1768662A2 (en)	2004-06-24	2007-04-04	Novartis Vaccines and Diagnostics, Inc.	Small molecule immunopotentiators and assays for their detection
US7151085B2 (en) *	2004-11-15	2006-12-19	Allergan, Inc.	Therapeutic methods using cyclosporine components
US7135455B2 (en) *	2004-11-15	2006-11-14	Allergan, Inc	Methods for the therapeutic use of cyclosporine components
US20070185150A1 (en)	2005-11-14	2007-08-09	Bedrosian Camille L	Therapeutic methods
RU2010104916A (ru) *	2006-08-16	2011-08-20	Михаил В. Благосклонный (US)	Способ профилактики и лечения возрастных заболеваний
RU2316005C1 (ru) *	2006-09-07	2008-01-27	Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского)	Способ оценки эффективности лечения пузырчатки
JP6049160B2 (ja)	2006-09-13	2016-12-27	エリクシアーメディカルコーポレイション	大環状ラクトン化合物およびその使用方法
ZA200902909B (en) *	2006-11-07	2010-07-28	Alcon Res Ltd	Method of treating asthma, allergic rhinitis, and skin disorders
WO2008063563A2 (en) *	2006-11-16	2008-05-29	Transderm, Inc.	Methods of treating keratin hyperproliferation disorders using mtor inhibitors
US20100086579A1 (en) *	2008-10-03	2010-04-08	Elixir Medical Corporation	Macrocyclic lactone compounds and methods for their use
BRPI1010655A2 (pt)	2009-04-10	2019-09-03	Qi Haiyan	novos agentes antienvelhecimento e métodos para identificá-los
AU2014209141B2 (en)	2013-01-24	2018-05-10	Palvella Therapeutics, Inc.	Compositions for transdermal delivery of mTOR inhibitors
EP3057601A4 (en) *	2013-10-14	2017-06-21	Izun Pharmaceuticals Corp.	Methods for treatment of m-tor inhibitor-associated stomatitis
HUP1400075A2 (hu)	2014-02-14	2015-08-28	Druggability Technologies Ip Holdco Jersey Ltd	Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
WO2016094732A1 (en) *	2014-12-10	2016-06-16	Transderm, Inc.	METHODS OF TREATING PAIN AND/OR ITCH WITH SMALL MOLECULE INHIBITORS TARGETING AN mTOR PATHWAY
CA3037469C (en)	2015-09-24	2024-04-16	Drexel University	Treatment of dermal disorders comprising a mtorc1 inhibitor
CN110520097B (zh)	2017-01-06	2023-10-27	帕尔维拉治疗股份有限公司	Mtor抑制剂的无水组合物及其使用方法
US10456383B2 (en) *	2017-06-01	2019-10-29	The Board Of Trustees Of The Leland Stanford Junior University	Targeted approach in the management of Epidermolysis bullosa
EP3817743A4 (en)	2018-07-02	2022-07-06	Palvella Therapeutics, Inc.	ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
JP2022511270A (ja) *	2018-08-30	2022-01-31	ケミストリーアールエックス．	シロリムス含有組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en) *	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US4023264A (en) *	1976-06-21	1977-05-17	Littelfuse, Inc.	Method of making miniature plug-in fuses of different fuse ratings
CH677448A5 (cs) *	1987-11-09	1991-05-31	Sandoz Ag
US4996193A (en) *	1989-03-03	1991-02-26	The Regents Of The University Of California	Combined topical and systemic method of administration of cyclosporine
US5023263A (en) *	1990-08-09	1991-06-11	American Home Products Corporation	42-oxorapamycin
JP2675194B2 (ja) *	1990-08-10	1997-11-12	スミスクライン・ビーチャム・コーポレイション	免疫抑制組成物
US5023262A (en) *	1990-08-14	1991-06-11	American Home Products Corporation	Hydrogenated rapamycin derivatives
US5078999A (en) *	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5080899A (en) *	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation

1992
- 1992-08-17 US US07/931,242 patent/US5286730A/en not_active Expired - Lifetime
- 1992-09-09 CZ CS922785A patent/CZ281900B6/cs not_active IP Right Cessation
- 1992-09-09 SK SK2785-92A patent/SK279521B6/sk unknown
- 1992-09-11 MX MX9205202A patent/MX9205202A/es not_active IP Right Cessation
- 1992-09-14 JP JP4244549A patent/JP2810599B2/ja not_active Expired - Fee Related
- 1992-09-14 ZA ZA927010A patent/ZA927010B/xx unknown
- 1992-09-15 NZ NZ328124A patent/NZ328124A/xx unknown
- 1992-09-15 AT AT92308384T patent/ATE151289T1/de not_active IP Right Cessation
- 1992-09-15 DE DE69218864T patent/DE69218864T2/de not_active Expired - Fee Related
- 1992-09-15 NZ NZ244340A patent/NZ244340A/xx unknown
- 1992-09-15 EP EP92308384A patent/EP0533433B1/en not_active Expired - Lifetime
- 1992-09-15 ES ES92308384T patent/ES2100297T3/es not_active Expired - Lifetime
- 1992-09-15 SG SG1996004061A patent/SG43126A1/en unknown
- 1992-09-15 DK DK92308384.4T patent/DK0533433T3/da active
- 1992-09-16 PH PH44946A patent/PH30270A/en unknown
- 1992-09-16 CA CA002078379A patent/CA2078379C/en not_active Expired - Fee Related
- 1992-09-16 HU HU9202955A patent/HU211112B/hu not_active IP Right Cessation
- 1992-09-16 KR KR1019920016795A patent/KR100299394B1/ko not_active Expired - Fee Related
- 1992-09-16 AU AU24507/92A patent/AU659868B2/en not_active Ceased
- 1992-09-16 IL IL11764092A patent/IL117640A/xx not_active IP Right Cessation
- 1992-09-16 IL IL10318992A patent/IL103189A/en not_active IP Right Cessation
- 1992-10-02 TW TW081107842A patent/TW212759B/zh active
1993
- 1993-06-15 UA UA93002912A patent/UA27742C2/uk unknown
1996
- 1996-03-25 IL IL11764096A patent/IL117640A0/xx unknown
1997
- 1997-06-04 GR GR970401324T patent/GR3023680T3/el unknown
- 1997-06-26 HK HK108697A patent/HK108697A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
ZA927010B (en)	1994-03-14
CA2078379C (en)	2003-07-29
NZ328124A (en)	2000-01-28
DK0533433T3 (da)	1997-05-12
IL117640A0 (en)	1996-07-23
MX9205202A (es)	1993-03-01
HU211112B (en)	1995-10-30
US5286730A (en)	1994-02-15
IL117640A (en)	1999-08-17
AU2450792A (en)	1993-03-18
DE69218864T2 (de)	1997-07-17
HU9202955D0 (en)	1992-12-28
SG43126A1 (en)	1997-10-17
HK108697A (en)	1997-08-22
KR100299394B1 (ko)	2001-10-22
JPH05194529A (ja)	1993-08-03
CZ278592A3 (en)	1993-04-14
UA27742C2 (uk)	2000-10-16
IL103189A0 (en)	1993-02-21
ATE151289T1 (de)	1997-04-15
GR3023680T3 (en)	1997-09-30
SK279521B6 (sk)	1998-12-02
DE69218864D1 (de)	1997-05-15
HUT64846A (en)	1994-03-28
JP2810599B2 (ja)	1998-10-15
TW212759B (cs)	1993-09-11
EP0533433A1 (en)	1993-03-24
AU659868B2 (en)	1995-06-01
ES2100297T3 (es)	1997-06-16
CZ281900B6 (cs)	1997-03-12
EP0533433B1 (en)	1997-04-09
NZ244340A (en)	1999-06-29
IL103189A (en)	1996-08-04
CA2078379A1 (en)	1993-03-18
SK278592A3 (en)	1995-03-08

Publication	Publication Date	Title
ZA927010B (en)	1994-03-14	Method or treating immunoinflammatory disease
EP0345302A4 (en)	1990-02-20	LIPOSOMIC VESICLES FOR THE INTRAPERITONEAL ADMINISTRATION OF THERAPEUTIC AGENTS.
ES2168302T3 (es)	2002-06-16	Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.
SI0730864T1 (en)	2004-02-29	Medicament for treating cardiac inflammatory diseases
ES2173111T3 (es)	2002-10-16	Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
EP0687175A4 (en)	1997-11-12	METHOD OF TREATING EMOTIONAL OR MENTAL ILLNESS, AND EMOTIONAL OR MENTAL ILLNESS CONCURRENT TO CRISIS
AU4180593A (en)	1994-01-13	The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
GR3034186T3 (en)	2000-11-30	3,4-diarylchromans for treatment of dermatitis
LT97135A (en)	1997-12-29	Use of melatonin in the manufacture of a medicament for treating patients suffering from drug addiction
GR3036691T3 (en)	2001-12-31	Dna sequences related to isolated fragile x syndrome
LV11728A (lv)	1997-04-20	Farmaceitiska kompozicija
CA2190837A1 (en)	1995-11-30	Transdermal delivery of anti-epileptic drugs
IT1293583B1 (it)	1999-03-08	Uso dell'acido gammaidrossibutirrico per il trattamento delle sindromi demenziali
USD435109S (en)	2000-12-12	Therapeutic treatment device
JPS6483020A (en)	1989-03-28	Medicinal composition for preventing or treating aids
NO990450L (no)	1999-01-29	Behandling av sinnslidelser
NZ307601A (en)	2000-04-28	Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
EP0286802A3 (en)	1992-01-08	Use of ofloxacin in treating or preventing locally periodontal disease
AU4250697A (en)	1998-03-19	Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
IL128494A0 (en)	2000-01-31	Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
IL135171A0 (en)	2001-05-20	Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
MX9800365A (es)	1998-03-29	Tratamiento de leucemia aguda con interleucina-10.
KR920009403A (ko)	1992-06-25	수면장해 치료용 이미다조벤조디아제핀
SI0829262T1 (en)	2002-06-30	Use of PKC inhibitors for the manufacture of a medicament for the treatment of sexual dysfunctions
EP0872238A3 (en)	1998-10-28	Use of olanzapine for the manufacture of a medicament for neuroprotection